Sonic Incytes Announces Multi-Year Partnership with Madrigal Pharmaceuticals to Advance Non-Invasive Liver Assessment in MASH
Partnership aims to help more clinicians assess and risk-stratify patients with or at risk for metabolic
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
![]()
Sonic Incytes Medical Corp., developer of the Velacur™ point-of-care liver assessment platform, today announced a multi-year partnership with Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for MASH, to advance the assessment and risk stratification of patients with or at risk for MASH.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119401533/en/
Velacur ONE®, Sonic Incytes’ AI-guided, point-of-care ultrasound elastography platform, provides real-time, non-invasive assessment of liver stiffness and fat to support clinical evaluation of patients at risk for MASH.
“MASH remains significantly underdiagnosed, and too many patients are missed or identified only after their disease has advanced,” said Barry Allen, President and CEO of Sonic Incytes. “We look forward to working with Madrigal to help clinicians deliver non-invasive liver assessments to the patients who need them, where they need them. We believe Velacur’s demonstrated accuracy, including our proprietary Velacur Determined Fat Fraction (VDFF), can help more patients be assessed earlier.”
The companies will work together to improve how patients at risk for MASH are identified, assessed and followed in clinical practice. The partnership will center on expanding the use of non-invasive tests (NITs) at the point of care, initially including gastroenterology, hepatology and endocrinology settings.
An estimated 80–100 million U.S. adults have metabolic dysfunction-associated steatotic liver disease (MASLD),1,2 and an estimated 15–20 million have MASH.1,3 As many as 90% of MASH cases remain undiagnosed.1,4,5 Left untreated, worsening MASH can progress to cirrhosis, liver failure, liver cancer, liver transplantation, or death.
Bringing Liver Assessment to the Point of Care
Current guidelines recommend non-invasive testing, including elastography, to assess liver fibrosis. Limited access to liver elastography in the community can delay assessment and follow-up.
Velacur, which received initial U.S. Food and Drug Administration 510(k) clearance in 2020, is an AI-guided ultrasound elastography device designed for use at the point of care. It measures liver stiffness using 3D S-WAVE, along with attenuation and VDFF. 3D S-WAVE has shown strong agreement with magnetic resonance elastography (MRE). VDFF has shown a strong correlation with MRI proton density fat fraction, the non-invasive gold standard for measuring liver fat. Velacur has also been validated against liver biopsy.
Unlike conventional elastography technologies, Velacur ONE combines AI guidance with 3D S-WAVE technology, which provides approximately 30 times greater sampling volume and up to twice the measurement depth compared with traditional vibration-controlled transient elastography (VCTE). These capabilities are designed to support consistent, reproducible assessments across a broad range of patients, including those with elevated BMI.
“Clinicians need practical tools that fit their existing workflows,” said Allen. “Madrigal has helped transform what is possible for people living with MASH. Together, we want to make objective liver assessment easy to access, so more patients can be identified and evaluated at the point of care.”
Supporting Clinical Workflows and the Patient Experience
Because Velacur ONE delivers real-time results in the clinic, liver health can be evaluated during a routine visit rather than through a separate referral. Results can help clinicians decide on next steps, including further evaluation or referral when appropriate. Treatment decisions remain with the clinician and patient.
A Shared Focus on Earlier Identification
The partnership reflects a broader shift toward treating liver health as part of comprehensive metabolic care. By combining Sonic Incytes’ point-of-care technology with Madrigal’s experience in MASH, the companies aim to support clinicians as they build more systematic approaches to identifying and assessing patients at risk.
About Sonic Incytes
Sonic Incytes is committed to enhancing patient care through innovative diagnostic solutions. The company’s flagship product, Velacur™, equips physicians with an advanced liver imaging tool to help manage the growing epidemic of fatty liver disease. Today, Velacur ONE offers real-time, AI-guided quantification of the key markers for fatty liver disease: liver stiffness, attenuation and VDFF. With real-time results, a low up-front cost and AI guidance, Velacur ONE makes liver imaging at the point of care affordable and accessible. For more information, visit www.sonicincytes.com.
About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company leading the fight against metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal has an approved therapy for MASH and a pipeline of investigational candidates targeting multiple pathways involved in liver disease progression. Through continued investment in innovation, Madrigal is committed to helping shape the future of MASH care and improving outcomes for patients. For more information, visit www.madrigalpharma.com.
References
- Le P, et al. Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw Open. 2025;8(1):e2454707.
- D. Kim, we al. Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023. Clin Mol Hepatol. 2025;31(2):382-393.
- Estes C, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123-133.
- Madrigal Pharmaceuticals, Inc. Annual Report on Form 10-K for fiscal year 2024.
- Lazarus JV, et al. A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis. Lancet Reg Health Eur. 2025.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261119401533/en/
Media gallery